Cite
N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits tumour necrosis factor-alpha (TNF-α) production on lipopolysaccharide (LPS)-stimulated human neutrophils.
MLA
Vulcano, M., et al. “N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) Inhibits Tumour Necrosis Factor-Alpha (TNF-α) Production on Lipopolysaccharide (LPS)-Stimulated Human Neutrophils.” Clinical & Experimental Immunology, vol. 113, no. 1, July 1998, pp. 39–47. EBSCOhost, https://doi.org/10.1046/j.1365-2249.1998.00631.x.
APA
Vulcano, M., Rosa, M. F. A., Minnucci, F. S., Cherñavsky, A. C., & Isturiz, M. A. (1998). N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits tumour necrosis factor-alpha (TNF-α) production on lipopolysaccharide (LPS)-stimulated human neutrophils. Clinical & Experimental Immunology, 113(1), 39–47. https://doi.org/10.1046/j.1365-2249.1998.00631.x
Chicago
Vulcano, M., M. F. Alves Rosa, F. S. Minnucci, A. C. Cherñavsky, and M. A. Isturiz. 1998. “N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) Inhibits Tumour Necrosis Factor-Alpha (TNF-α) Production on Lipopolysaccharide (LPS)-Stimulated Human Neutrophils.” Clinical & Experimental Immunology 113 (1): 39–47. doi:10.1046/j.1365-2249.1998.00631.x.